Study guide

7.3 HIV/AIDS Management, Antiretroviral Therapy (ART) & Opportunistic Infections

Nursing and Midwifery Council of Ghana Licensing Examinations Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: N&MC Ghana Regulation, Licensing Pathway & Examination Format

1.1 Health Professions Regulatory Bodies Act, 2013 (Act 857) & the N&MC Mandate 1.2 Cadres, Indexing, Eligibility, Examination Windows & Fees 1.3 Registration, PIN vs. AIN, Rotation, Licence Renewal & Foreign-Trained Pathway 1.4 Examination Format: Computer-Based Papers, Practical Component, Results & Re-sits

2 Chapter 2: Professional Ethics, Law, Leadership & Patient Rights

2.1 N&MC Ghana Code of Conduct, Ethical Principles & Professional Boundaries 2.2 Ghana Health Service Patients' Charter, Informed Consent & Confidentiality 2.3 Clinical Documentation, Incident Reporting, Negligence & Legal Liability 2.4 Nursing Leadership, Ward Management, Handover & Team Communication

3 Chapter 3: Infection Prevention, Control & Healthcare Safety

3.1 Standard & Transmission-Based Precautions, Hand Hygiene & PPE 3.2 Sterilization, Decontamination & Healthcare Waste Management in Ghana 3.3 Injection Safety, Sharps Injury Prevention & Occupational Post-Exposure Prophylaxis

4 Chapter 4: Clinical Nursing Foundations, Nursing Process & Practical Skills

4.1 Vital Signs Assessment, Clinical Deterioration & Early Warning Scoring 4.2 Medication Administration, Dosages, High-Alert Drugs & Pharmacovigilance 4.3 Enteral & Parenteral Nutrition, Fluid and Electrolyte Balance & Acid-Base Disorders 4.4 Pain Assessment, Analgesic Ladder & Palliative Care in Ghana 4.5 Nursing Process, Care Plans, Care Study & the Practical Examination

5 Chapter 5: Respiratory, Cardiovascular & Neurological Nursing

5.1 Airway, Breathing & Oxygen Therapy: Asthma, COPD & Pneumonia 5.2 Acute Coronary Syndromes, Heart Failure & Shock Classifications 5.3 Hypertension Management, Hypertensive Emergencies & Stroke Care 5.4 Neurological Nursing: Unconscious Patient, Head Injury, Raised ICP & Epilepsy

6 Chapter 6: Endocrine, Renal, Gastrointestinal & Liver Disorders

6.1 Diabetes Mellitus, DKA, HHS & Glycemic Emergencies 6.2 Acute Kidney Injury, Chronic Kidney Disease & Fluid Overload 6.3 Acute Abdomen, Peptic Ulcer Disease & Gastrointestinal Bleeding 6.4 Liver Disease (Hepatitis B, Cirrhosis, Hepatic Encephalopathy) & Thyroid Disorders

7 Chapter 7: Endemic Tropical Infections & Communicable Diseases

7.1 Malaria Management: Diagnostics, Uncomplicated & Severe Malaria Protocols 7.2 Tuberculosis Diagnosis, DOTS Protocol & Infection Control 7.3 HIV/AIDS Management, Antiretroviral Therapy (ART) & Opportunistic Infections 7.4 Enteric Infections: Cholera, Typhoid Fever & Diarrhoea Outbreak Response

8 Chapter 8: Hematology & Common Non-Communicable Conditions

8.1 Sickle Cell Disease: Vaso-Occlusive Crises, Anemia & Organ Protection 8.2 Blood Transfusion Practice, Crossmatching & Transfusion Reactions 8.3 Venous Thromboembolism, Anticoagulation & Pressure Injury Prevention

9 Chapter 9: Perioperative, Urological & Gynaecological Surgical Nursing

9.1 Preoperative Evaluation, Patient Preparation & Informed Consent 9.2 Intraoperative Care, Surgical Asepsis & WHO Surgical Safety Checklist 9.3 Postoperative Complications, Wound Healing & Dressing Techniques 9.4 Anesthesia Overview, Recovery Room (PACU) Care & Pain Management 9.5 Urological Surgical Nursing: Retention, BPH, Prostatectomy, Calculi & Catheter Care 9.6 Gynaecological Nursing: Ectopic Pregnancy, Abortion Care, Fibroids, PID & Cancer Screening

10 Chapter 10: Trauma, Burns & Acute Emergency Management

10.1 ABCDE Primary/Secondary Survey & Disaster Triage (START) 10.2 Major Burns: Rule of Nines, Parkland Fluid Resuscitation & Wound Care 10.3 Fractures, Immobilization, Compartment Syndrome & Spinal Precautions 10.4 Environmental Emergencies: Snakebites, Poisoning & Tetanus Prophylaxis

11 Chapter 11: Maternal Health, Obstetric & Postnatal Nursing

11.1 Antenatal Care (ANC/FANC), Risk Assessment & Health Promotion 11.2 Normal Labor, Stages & Partograph Monitoring 11.3 Obstetric Complications: Postpartum Hemorrhage (PPH) & Active Third Stage (AMTSL) 11.4 Hypertensive Disorders of Pregnancy: Preeclampsia, Eclampsia & MgSO4 11.5 Postnatal Care, Breastfeeding Support & Family Planning

12 Chapter 12: Neonatal & Pediatric Nursing Care

12.1 Immediate Newborn Care, APGAR Scoring & Neonatal Resuscitation 12.2 Integrated Management of Neonatal & Childhood Illness (IMNCI) 12.3 Ghana Expanded Programme on Immunization (EPI) & Pediatric Malnutrition

13 Chapter 13: Community Health Nursing & Primary Healthcare in Ghana

13.1 Community-Based Health Planning and Services (CHPS) Model 13.2 Disease Surveillance, Epidemic Preparedness & Community Health Education 13.3 Environmental Sanitation, Water Safety & School Health Services

14 Chapter 14: Mental Health Nursing & Psychiatric Care

14.1 Mental Health Act, 2012 (Act 846): Authority, Admission Routes & Rights 14.2 Common Psychiatric Disorders: Depression, Bipolar, Schizophrenia & Psychosis 14.3 Psychiatric Emergencies: Suicide Risk Assessment & De-escalation

7.3 HIV/AIDS Management, Antiretroviral Therapy (ART) & Opportunistic Infections

Key Takeaways Explain This Topic AI

HIV infects and depletes CD4+ T-helper lymphocytes; progressive immune exhaustion triggers opportunistic infections and malignancies as CD4 counts decline below 200 cells/uL (defining AIDS).

HIV testing services in Ghana adhere to the '5 Cs' (Consent, Confidentiality, Counselling, Correct results, Connection to care) using a validated serial rapid diagnostic algorithm.

Under Ghana's universal 'Test and Treat' policy, lifelong antiretroviral therapy is initiated immediately upon confirmed diagnosis regardless of CD4 count or clinical stage, utilizing first-line single-tablet Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir (TLD).

Prevention of Mother-to-Child Transmission (PMTCT) employs Option B+ (lifelong maternal TLD), infant daily Nevirapine syrup for 6 weeks, and Early Infant Diagnosis via HIV DNA PCR testing at 4 to 6 weeks of age.

Co-trimoxazole preventive therapy (CPT) provides broad protection against Pneumocystis jirovecii pneumonia, toxoplasmosis, and severe bacterial infections in individuals with CD4 < 350 cells/uL or WHO Stage 3/4 disease.

Last updated: September 2026

7.3 HIV/AIDS Management, Antiretroviral Therapy (ART) & Opportunistic Infections

Quick Answer: Human Immunodeficiency Virus (HIV) infection is a chronic retroviral disease characterized by progressive destruction of CD4+ T-helper lymphocytes, culminating in profound cell-mediated immunodeficiency and acquired immunodeficiency syndrome (AIDS). In Ghana, HIV testing services follow the "5 Cs" (Consent, Confidentiality, Counselling, Correct results, Connection to care) using a serial rapid diagnostic algorithm. Under the Ghana National AIDS/STI Control Programme (NACP) "Test and Treat" policy , all individuals confirmed positive initiate lifelong Antiretroviral Therapy (ART) immediately, regardless of CD4 cell count or WHO clinical stage. The preferred first-line regimen is the once-daily fixed-dose combination TLD (Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir). Key priorities include proactive toxicity monitoring, Option B+ PMTCT execution, timely prophylaxis against Pneumocystis jirovecii pneumonia, and vigilant management of opportunistic infections to prevent fatal Immune Reconstitution Inflammatory Syndrome (IRIS).

Virology, Transmission, and Pathophysiology

HIV belongs to the genus Lentivirus within the family Retroviridae . Two major types infect humans: HIV-1 , distributed globally with high pathogenicity and transmission efficiency, and HIV-2 , concentrated largely in West Africa (including Ghana). HIV-2 is characterized by lower plasma viral loads, slower CD4 decline, lower rates of vertical transmission, and intrinsic structural resistance to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). THE HIV REPLICATION CYCLE

  • |
  • 1. ATTACHMENT & BINDING: Viral gp120 binds CD4 receptor
  • + chemokine co-receptor (CCR5 or CXCR4)
  • |
  • 2. FUSION & ENTRY: gp41 conformational change mediates
  • viral envelope fusion with host cell membrane
  • |
  • 3. REVERSE TRANSCRIPTION: Viral RNA converted to double-stranded
  • cDNA via Reverse Transcriptase (Target of NRTIs & NNRTIs)
  • |
  • 4. INTEGRATION: Viral cDNA transported to nucleus and spliced
  • into human genome by Integrase enzyme (Target of INSTIs like DTG)
  • |
  • 5. TRANSCRIPTION & TRANSLATION: Host RNA polymerase transcribes
  • proviral DNA into viral mRNA and polyprotein precursors
  • |
  • 6. ASSEMBLY: Core proteins, viral genomic RNA, and enzymes
  • package beneath host plasma membrane
  • |
  • 7. BUDDING & MATURATION: Immature virion buds off; viral Protease
  • cleaves polyproteins to form mature infectious virion (Target of PIs)
  • Cellular Pathogenesis and CD4 Depletion

The viral envelope surface glycoprotein gp120 binds with high affinity to the primary CD4 receptor expressed on T-helper lymphocytes, monocytes, macrophages, and dendritic cells. This induces a conformational shift allowing gp120 to bind a chemokine co-receptor—either CCR5 (macrophage-tropic, predominant during early transmission) or CXCR4 (T-cell tropic, emerging during late disease). Transmembrane glycoprotein gp41 then mediates membrane fusion, releasing the viral capsid containing two identical single-stranded RNA molecules and viral enzymes (reverse transcriptase, integrase, protease) into the host cytoplasm.

Following integration into the host genome, HIV establishes a lifelong proviral state. Progressive depletion of CD4+ T-helper cells occurs through direct viral cytolysis, syncytium formation, apoptosis of uninfected bystander cells, and CD8+ cytotoxic T-lymphocyte destruction of infected cells. When CD4+ counts fall below critical thresholds, cell-mediated immunity fails, permitting reactivation of latent pathogens and fatal opportunistic malignancies.

Transmission Routes in Ghana

Unprotected Heterosexual Intercourse: Accounts for over 80% of infections in Ghana.

Mother-to-Child Transmission (MTCT): Occurs during pregnancy (antepartum), labor and delivery (intrapartum), or through breastfeeding (postpartum).

Parenteral / Percutaneous Inoculation: Unscreened blood transfusions, contaminated needle reuse, and accidental occupational sharps injuries.

WHO Clinical Staging System (Stages 1 through 4)

The WHO staging framework categorizes clinical disease severity to guide clinical decisions, evaluate prognosis, and determine opportunistic infection risks:

WHO Clinical Stage Clinical Manifestations & Defining Conditions Diagnostic & Clinical Significance

Stage 1 (Asymptomatic) - Asymptomatic infection; - Persistent Generalized Lymphadenopathy (PGL: painless, non-tender, symmetrical lymph nodes > 1 cm > 1\text{ cm} > 1 cm in ≥ 2 \ge 2 ≥ 2 extra-inguinal sites for > 3 > 3 > 3 months) Normal immune function; CD4 typically > 500 cells/ μ L > 500\text{ cells/}\mu\text{L} > 500 cells/ μ L

Stage 2 (Mild Symptoms) - Unexplained moderate weight loss ( < 10 % < 10\% < 10% of body weight); - Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media); - Herpes zoster (shingles) within last 5 years; - Angular cheilitis, recurrent oral ulcerations; - Papular pruritic eruptions, fungal nail infections (onychomycosis), seborrheic dermatitis Mild immune deficiency; CD4 typically 350 – 500 cells/ μ L 350\text{--}500\text{ cells/}\mu\text{L} 350 – 500 cells/ μ L

Stage 3 (Advanced Disease) - Unexplained severe weight loss ( > 10 % > 10\% > 10% of body weight); - Unexplained chronic diarrhea lasting > 1 month > 1\text{ month} > 1 month ; - Unexplained persistent fever ( > 37.5 ∘ C > 37.5^\circ\text{C} > 37. 5 ∘ C , intermittent or constant) lasting > 1 month > 1\text{ month} > 1 month ; - Persistent oral candidiasis (thrush); - Oral hairy leukoplakia (Epstein-Barr virus); - Pulmonary tuberculosis (diagnosed within past 2 years); - Severe bacterial infections (pneumonia, empyema, pyomyositis, meningitis); - Unexplained anemia ( < 8 g/dL < 8\text{ g/dL} < 8 g/dL ), neutropenia ( < 0.5 × 10 9 /L < 0.5 \times 10^9\text{/L} < 0.5 × 1 0 9 /L ), thrombocytopenia Advanced immune deficiency; CD4 typically 200 – 350 cells/ μ L 200\text{--}350\text{ cells/}\mu\text{L} 200 – 350 cells/ μ L ; mandatory Co-trimoxazole preventive therapy (CPT) indication

Stage 4 (Severe / AIDS) - HIV Wasting Syndrome (severe weight loss > 10 % > 10\% > 10% with chronic diarrhea or fever); - Pneumocystis jirovecii pneumonia (PJP/PCP) ; - Recurrent severe bacterial pneumonia ( ≥ 2 \ge 2 ≥ 2 episodes in 12 months); - Chronic herpes simplex infection (orolabial or genital > 1 month > 1\text{ month} > 1 month ); - Esophageal candidiasis ; - Extrapulmonary tuberculosis (lymph node, pleural, pericardial, miliary); - Cryptococcal meningitis ; - Toxoplasmosis of the brain ; - Kaposi sarcoma ( HHV-8 ), Invasive cervical carcinoma, Non-Hodgkin lymphoma; - Cytomegalovirus (CMV) retinitis or organ disease Severe immune failure; CD4 < 200 cells/ μ L < 200\text{ cells/}\mu\text{L} < 200 cells/ μ L ; high short-term mortality without immediate intervention

Testing Modalities & Ghana National Testing Algorithm

HIV testing in Ghana is executed via Provider-Initiated Testing and Counselling (PITC) in all health facilities and Voluntary Counselling and Testing (VCT) in community centers, anchored strictly to the 5 Cs :

Consent: Verbal informed consent; patients maintain the right to decline (opt-out approach).

Confidentiality: Results shared solely between patient and healthcare team.

Counselling: Pre-test information and comprehensive post-test counselling.

Correct Results: Adherence to strict quality-controlled testing algorithms.

Connection to Care: Immediate active linkage to ART initiation on the same day.

Ghana Serial Rapid Testing Algorithm

Ghana uses a nationally validated serial algorithm of rapid tests (the specific kits change with national procurement and are listed in the current national testing guidelines): GHANA SERIAL RAPID TESTING ALGORITHM

  • |
  • [TEST 1: SCREENING ASSAY]
  • (first approved kit)
  • |
  • +----------------+----------------+
  • | |
  • NON-REACTIVE REACTIVE
  • | |
  • REPORT NEGATIVE [TEST 2: CONFIRMATORY ASSAY]
  • (second approved kit)
  • |
  • +----------------+----------------+
  • | |
  • REACTIVE NON-REACTIVE
  • | (DISCORDANT)
  • REPORT POSITIVE |
  • (Specify HIV-1, HIV-2, [TEST 3: TIE-BREAKER]
  • or Dual) (third kit)
  • |
  • +----------------+----------------+
  • | |
  • REACTIVE NON-REACTIVE
  • | |
  • REPORT POSITIVE REPORT INCONCLUSIVE
  • (Retest in 14 days)

Test 1 (Screening Assay): High-sensitivity assay (first approved kit). If non-reactive, the client is confirmed HIV Negative (counsel on window period if recent exposure occurred).

Test 2 (Confirmatory Assay): If Test 1 is reactive, perform a high-specificity confirmatory assay (second approved kit). If both tests are reactive, report HIV Positive and differentiate type (HIV-1, HIV-2, or dual infection).

Test 3 (Tie-Breaker Assay): If Test 1 is reactive but Test 2 is non-reactive (discordant result), run a third assay (third kit). If Test 3 is reactive, report HIV Positive . If Test 3 is non-reactive, report Inconclusive ; instruct client to return in 14 to 28 days for a repeat test to resolve possible seroconversion window period dynamics.

Ghana ART Guidelines: "Test and Treat" & First-Line Regimens

Under the Ghana NACP guidelines, Ghana implements a universal "Test and Treat" policy : all children, adolescents, and adults confirmed to be living with HIV must be initiated on lifelong Antiretroviral Therapy (ART) immediately—preferably on the same day as diagnosis , and no later than 7 days—regardless of CD4 cell count or clinical staging, provided clinical stability is confirmed.

Preferred Adult First-Line Regimen: TLD Single-Tablet Combination

The preferred first-line regimen for adults, adolescents, and women of childbearing potential is a once-daily fixed-dose combination tablet consisting of:

  • Tenofovir Disoproxil Fumarate (TDF) 300 mg: Nucleotide Reverse Transcriptase Inhibitor (NtRTI)
  • Lamivudine (3TC) 300 mg: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
  • Dolutegravir (DTG) 50 mg: Integrase Strand Transfer Inhibitor (INSTI)
  • Advantages of Dolutegravir (DTG)-Based Regimens

Dolutegravir has superseded Efavirenz (EFV) due to its high genetic barrier to resistance, rapid achievement of plasma viral suppression (typically within 4 to 8 weeks), once-daily administration, low incidence of adverse effects, and absence of cross-resistance to first-generation NNRTIs.

Alternative Regimens

In patients with pre-existing renal impairment (eGFR < 50 mL/min < 50\text{ mL/min} < 50 mL/min ): Substitute TDF with Abacavir (ABC) , yielding ABC + 3TC + DTG .

If DTG is unavailable or contraindicated: Use TDF + 3TC + Efavirenz (EFV 400 mg) .

Drug Toxicities & Pharmacovigilance

Antiretroviral Agent Drug Class Common Adverse Effects Severe Toxicities & Nursing Management

Tenofovir Disoproxil Fumarate (TDF) NtRTI Nausea, flatulence, headache Proximal renal tubular dysfunction (Fanconi syndrome) , decline in eGFR, and decrease in bone mineral density. Nursing Action: Check baseline serum creatinine and dipstick urine protein; monitor eGFR every 6 to 12 months; switch to Abacavir if eGFR drops < 50 mL/min < 50\text{ mL/min} < 50 mL/min .

Dolutegravir (DTG) INSTI Insomnia, headache, mild nausea, diarrhea Significant weight gain and rare hypersensitivity reactions. Nursing Action: Instruct patient to take DTG in the morning if insomnia occurs; monitor BMI, fasting lipid profile, and glycemic control.

Efavirenz (EFV) NNRTI Dizziness, headache, rash Central Nervous System toxicities (vivid dreams, nightmares, insomnia, severe depression, psychosis, confusion). Nursing Action: Administer at bedtime on an empty stomach (fatty meals dramatically increase drug levels and toxicity); contraindicated in patients with severe psychiatric disorders.

Zidovudine (AZT) NRTI Nausea, myopathy, hyperpigmentation of nails Severe bone marrow suppression (macrocytic anemia and severe neutropenia). Nursing Action: Baseline Hb and CBC required; hold AZT and substitute TDF/ABC if hemoglobin drops < 8.0 g/dL < 8.0\text{ g/dL} < 8.0 g/dL .

Prevention of Mother-to-Child Transmission (PMTCT: Option B+)

Without intervention, the risk of vertical transmission ranges from 15% to 45%. With full PMTCT implementation, transmission drops below 2% in non-breastfeeding populations and below 5% in breastfeeding populations.

Option B+ Maternal Strategy: Every pregnant or breastfeeding woman diagnosed with HIV is immediately initiated on lifelong TLD fixed-dose combination , irrespective of CD4 cell count, gestational age, or clinical stage. ART must be continued uninterrupted through pregnancy, labor, delivery, breastfeeding, and for life.

Labor & Delivery Safeguards: Practice universal precautions; avoid prolonged rupture of membranes (> 4 hours); avoid invasive procedures including artificial rupture of membranes (ARM), fetal scalp electrodes, and routine episiotomy; gently wipe infant mouth and nose clear of maternal blood and secretions immediately upon delivery.

Infant Post-Exposure Prophylaxis (PEP): Administer daily oral Nevirapine (NVP) syrup to the newborn starting within 72 hours of birth (preferably within 4 hours) and continued daily for 6 weeks for standard-risk infants. If the mother had a viral load > 1,000 copies/mL > 1{,}000\text{ copies/mL} > 1 , 000 copies/mL at delivery or was on ART for < 4 weeks < 4\text{ weeks} < 4 weeks , extend infant prophylaxis to 12 weeks with dual therapy (Nevirapine + Zidovudine).

Infant Feeding Guidance in Ghana: Mothers receiving ART and virally suppressed are encouraged to practice exclusive breastfeeding for the first 6 months , followed by introducing safe complementary foods while continuing breastfeeding up to 12 to 24 months. Mixed feeding (breastmilk combined with formula or other liquids) in the first 6 months is strictly avoided, as foreign proteins disrupt mucosal integrity and dramatically increase HIV transmission.

Early Infant Diagnosis (EID) Protocol: Maternal IgG antibodies cross the placenta, persisting in infant circulation up to 18 months; therefore, rapid antibody tests produce false positives. Definitive infant diagnosis requires direct detection of viral genetic material via HIV DNA Polymerase Chain Reaction (PCR) :

First Test: At 4 to 6 weeks of age (or first clinical contact).

Second Test: At 9 months of age .

Final Confirmatory Test: 6 weeks after complete cessation of breastfeeding (using rapid antibody test if child is ≥ 18 months \ge 18\text{ months} ≥ 18 months ). If any DNA PCR is positive, confirm with a second sample and immediately initiate pediatric ART.

Opportunistic Infections & Immune Reconstitution Inflammatory Syndrome (IRIS)

Opportunistic Infection Etiology & Risk Level Diagnostic Signs & Symptoms Prophylaxis & Acute Pharmacotherapy

Pneumocystis jirovecii Pneumonia (PJP / PCP) Atypical fungus; CD4 < 200 cells/ μ L < 200\text{ cells/}\mu\text{L} < 200 cells/ μ L Subacute dry cough, progressive exertional dyspnea, fever, tachypnea; bilateral diffuse perihilar interstitial infiltrates on CXR; normal breath sounds or faint crackles Prophylaxis: Daily Co-trimoxazole (TMP-SMX 960 mg) in all patients with CD4 < 350 cells/ μ L < 350\text{ cells/}\mu\text{L} < 350 cells/ μ L or Stage 3/4.; Treatment: High-dose IV/oral Co-trimoxazole (TMP 15-20 mg/kg/day + SMX 75-100 mg/kg/day) for 21 days + prednisolone if PaO 2 < 70 mmHg \text{PaO}_2 < 70\text{ mmHg} PaO 2 ​ < 70 mmHg .

Cryptococcal Meningitis Encapsulated yeast ( Cryptococcus neoformans ); CD4 < 100 cells/ μ L < 100\text{ cells/}\mu\text{L} < 100 cells/ μ L Subacute headache, fever, neck stiffness, photophobia, confusion; lumbar puncture shows markedly elevated opening pressure ( > 200 mmH 2 O > 200\text{ mmH}_2\text{O} > 200 mmH 2 ​ O ); positive CSF India ink staining and Cryptococcal Antigen (CrAg) Treatment: WHO (2022) preferred induction: a single high dose of liposomal amphotericin B with 14 days of flucytosine and fluconazole (alternative: one week of amphotericin B deoxycholate with flucytosine), followed by fluconazole consolidation and maintenance.; Exam Alert: Defer ART for 4 to 6 weeks after starting antifungal therapy!

Oral & Esophageal Candidiasis Candida albicans ; Oral: CD4 < 350 < 350 < 350 ; Esophageal: CD4 < 100 < 100 < 100 Oral thrush: removable white curd-like plaques on buccal mucosa; Esophageal candidiasis: severe retrosternal burning, painful swallowing (odynophagia), and dysphagia Oral Thrush: Nystatin oral suspension or oral Fluconazole 100 mg 100\text{ mg} 100 mg daily for 7 days.; Esophageal: Oral/IV Fluconazole 200 – 400 mg 200\text{--}400\text{ mg} 200 – 400 mg daily for 14 to 21 days.

Cerebral Toxoplasmosis Intracellular protozoan ( Toxoplasma gondii ); CD4 < 100 cells/ μ L < 100\text{ cells/}\mu\text{L} < 100 cells/ μ L Headache, focal neurological deficits (hemiparesis, aphasia), seizures, fever; Brain CT/MRI shows multiple ring-enhancing lesions with surrounding vasogenic edema Prophylaxis: Co-trimoxazole daily provides complete coverage.; Treatment: Pyrimethamine + Sulfadiazine + Folinic acid for 6 weeks; high-dose Co-trimoxazole is the standard Ghanaian alternative.

Caution

Immune Reconstitution Inflammatory Syndrome (IRIS): Following ART initiation, vigorous restoration of pathogen-specific cellular immunity can provoke an exaggerated inflammatory response against residual antigens of treated or occult infections (most commonly M. tuberculosis or Cryptococcus ). Manifestations include high fevers, worsening lymphadenopathy, and enlarging intracranial lesions. Management requires continuing ART, treating the underlying opportunistic pathogen aggressively, and administering systemic corticosteroids in life-threatening inflammatory states.